Boardroom Alpha
Boardroom Alpha
VCEL · Additional Proxy Materials (DEFA14A) · Filed March 19, 2026

Vericel Corp — Additional Proxy Materials (DEFA14A)

Form
DEFA14A
Filed
March 19, 2026
Ticker
VCEL
Accession
0001308179-26-000095
Boardroom Alpha · Filing insights

Vericel's board recommends voting For all three proposals at the 2026 annual meeting (director slate, executive compensation, auditor).

About Vericel Corp
Market cap
$1.8B
1Y TSR
−18.8%
3Y TSR
−0.3%
Board grade
B
Sector
Healthcare
CEO
Dominick Colangelo
Last annual meeting: Apr 29, 2026 · View full Vericel Corp profile →
VERICEL CORPORATION - DEFA 14A

UNITED STATES

 

SECURITIES AND EXCHANGE COMMISSION

 

Washington, DC 20549

 

SCHEDULE 14A

 

PROXY STATEMENT PURSUANT TO SECTION 14(a)
OF THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No.     )

 

  Filed by the Registrant   Filed by a Party other than the Registrant

 

Check the appropriate box:
Preliminary Proxy Statement
Confidential, for Use of the Commission Only (as permitted by Rule 14A-6(E)(2))
Definitive Proxy Statement
Definitive Additional Materials
Soliciting Material under §240.14a-12

 

VERICEL CORPORATION

 

 

(Name of Registrant as Specified in Its Charter)

 

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

 

Payment of Filing Fee (Check all boxes that apply):
No fee required.
Fee paid previously with preliminary materials.
Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.
 

 

      Your Vote Counts!  
                                 VERICEL CORPORATION  
      2026 Annual Meeting of Shareholders  
      Vote by April 28, 2026  
   

 



VERICEL CORPORATION
ATTN: SEAN C. FLYNN
64 SIDNEY STREET
CAMBRIDGE, MA 02139

  11:59 PM ET  
       
       
         
         
         
         
         
         
           V83886-P45794      

 

You invested in VERICEL CORPORATION and it’s time to vote!

You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding the availability of proxy materials for the Annual Meeting of Shareholders to be held on April 29, 2026 at 9:00 a.m. ET.

 

Get informed before you vote

View the 2026 Notice of Virtual Annual Meeting of Shareholders and Proxy Statement and Form 10-K online OR you can receive a free paper or email copy of the voting materials by requesting prior to April 15, 2026. If you would like to request a copy of the voting materials, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to sendmaterial@proxyvote.com. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy.

 

     
For complete information and to vote, visit www.ProxyVote.com
Control #
     

 

Smartphone users

 

Point your camera here and
vote without entering a
control number

   

Vote Virtually at the Meeting*

 

April 29, 2026
9:00 a.m. ET


 

 

Virtually at:
www.virtualshareholdermeeting.com/VCEL2026

 

Vote by Mail

You can vote by mail by requesting a paper copy of the materials, which will include a proxy card.

       

 

*Vericel will be hosting the Annual Meeting live via the Internet. You will not be able to attend the Annual Meeting in person. You can listen to and participate in the Annual Meeting live via the Internet at www.virtualshareholdermeeting.com/VCEL2026. The Annual Meeting webcast will begin promptly at 9:00 a.m. ET on April 29, 2026. We encourage you to access the Annual Meeting webcast prior to the start time. You will need the 16-digit control number listed above to be able to vote these shares during the Annual Meeting. Instructions on how to connect to the Annual Meeting and participate via the Internet, including how to demonstrate proof of stock ownership, will be posted at www.virtualshareholdermeeting.com/VCEL2026 two weeks prior to the date of the Annual Meeting.

 
Vote at www.ProxyVote.com  

 

THIS IS NOT A VOTABLE BALLOT

 

This is an overview of the proposals being presented at the upcoming shareholder meeting. Please follow the instructions on the reverse side to vote these important matters.

   

 

Voting Items Board
Recommends
1. Election of Directors  
  Nominees:              
 

01)  Robert L. Zerbe

02)  Alan L. Rubino

03)  Heidi Hagen

04)  Kevin F. McLaughlin

         

05)  Paul K. Wotton

06)  Dominick C. Colangelo

07)  Lisa Wright

 

For
2. To approve, on an advisory basis, the compensation of Vericel Corporation’s named executive officers. For
3. To ratify the appointment of PricewaterhouseCoopers LLP as Vericel Corporation’s independent registered public accounting firm for the fiscal year ending December 31, 2026. For
NOTE: In their discretion, the proxies are authorized to vote upon any other matters that are properly brought by or at the direction of the Board of Directors before the Annual Meeting and at any adjournments or postponements thereof. Even if you are planning to attend the meeting virtually, you are urged to sign and mail this Proxy in the return envelope so that the stock may be represented at the meeting.
   
   
Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click “Delivery Settings”.
 
V83887-P45794
 
From this filing to the vote

Forecast every director vote the day the proxy files.

Meeting Forecast scores each director up for re-election + every contested situation, rebuilt daily across 6,000+ U.S. public companies. The same model that called the LULU contested proxy lives on every meeting you see here.

Independent — issuer-pays-free, ideology-free, U.S.-owned.

More filings

Other filings from Vericel Corp (VCEL)

Reference

Frequently asked questions

When did Vericel Corp file this DEFA14A?
Vericel Corp (VCEL) filed this Additional Proxy Materials (DEFA14A) with the SEC on March 19, 2026. The accession number assigned by EDGAR is 0001308179-26-000095.
What does a DEFA14A disclose?
DEFA14A is additional definitive proxy soliciting material filed in connection with a shareholder meeting — supplemental letters, slides, or amendments issued after the main proxy statement.
What is the key takeaway from this filing?
Vericel's board recommends voting For all three proposals at the 2026 annual meeting (director slate, executive compensation, auditor). This is Boardroom Alpha's one-line summary of the additional proxy materials; see the full filing text above for the formal disclosure.
Where can I find Vericel Corp's prior proxy statements on EDGAR?
The SEC EDGAR browser lists every DEFA14A Vericel Corp has filed under CIK 887359, sortable by date. Use the "View on SEC EDGAR" link in the page header, or browse directly via https://www.sec.gov/cgi-bin/browse-edgar.
Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer